Biopharmaceutical company MediciNova, Inc. announced the initiation of a Phase II clinical study to determine the safety and efficacy of MN-305 for the treatment of insomnia.

MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development both for the treatment of insomnia as well as for anxiety disorders such as generalized anxiety disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of mutagenicity, antigenicity or carcinogenicity. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects.

MediciNova acquired a license to MN-305 from Mitsubishi Pharma Corporation for global markets, with the exception of Japan and other selected Asian countries.

Source: MediciNova